Zacks Investment Research downgraded shares of Catalyst Biosciences (NASDAQ:CBIO) from a buy rating to a hold rating in a research note published on Monday morning.
According to Zacks, “Catalyst Biosciences, Inc. is a biopharmaceutical company which focused on creating and developing medicines to address serious medical conditions. The Company’s hemostasis product candidates include CB 813d/PF-0520602, CB 2679d/ISU 304 and FXa. Anti-Complement Product consists of CB 2782 and Ophthalmic which are in clinical different trail. Catalyst Biosciences, Inc., formerly known as Targacept, Inc., is based in South San Francisco, Calif. “
Separately, B. Riley set a $19.00 price objective on shares of Catalyst Biosciences and gave the company a buy rating in a research report on Monday, December 18th.
A number of large investors have recently added to or reduced their stakes in CBIO. Virtu KCG Holdings LLC bought a new position in Catalyst Biosciences during the second quarter worth about $103,000. Bank of New York Mellon Corp bought a new position in Catalyst Biosciences during the second quarter worth about $107,000. Zacks Investment Management bought a new position in Catalyst Biosciences during the second quarter worth about $147,000. Vanguard Group Inc. increased its position in Catalyst Biosciences by 294.1% during the second quarter. Vanguard Group Inc. now owns 43,714 shares of the biopharmaceutical company’s stock worth $204,000 after acquiring an additional 32,621 shares during the period. Finally, Dimensional Fund Advisors LP bought a new position in Catalyst Biosciences during the second quarter worth about $372,000. 28.39% of the stock is currently owned by institutional investors and hedge funds.
About Catalyst Biosciences
Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.